<div id="readability-page-1"><p>Portside Wealth Group LLC cut its stake in shares of  Abbott Laboratories (NYSE:ABT - Free Report) by 41.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor  owned 19,016 shares of the healthcare product maker's stock after selling 13,652 shares during the quarter. Portside Wealth Group LLC's holdings in Abbott Laboratories were worth $2,382,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Abbott Laboratories</strong> alerts:</span></p></div><ul><li>AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal</li></ul><p>Several other institutional investors and hedge funds have also recently modified their holdings of ABT. Lakeshore Capital Group Inc. increased its position in shares of  Abbott Laboratories by 4.0% during the fourth quarter. Lakeshore Capital Group Inc. now owns 7,367 shares of the healthcare product maker's stock valued at $923,000 after acquiring an additional 280 shares in the last quarter.  Sound Income Strategies LLC increased its position in shares of  Abbott Laboratories by 6.8% during the fourth quarter. Sound Income Strategies LLC now owns 2,130 shares of the healthcare product maker's stock valued at $259,000 after acquiring an additional 135 shares in the last quarter.  Rathbones Group PLC increased its position in shares of  Abbott Laboratories by 3.6% during the fourth quarter. Rathbones Group PLC now owns 3,116,386 shares of the healthcare product maker's stock valued at $390,452,000 after acquiring an additional 107,648 shares in the last quarter.  Guild Investment Management Inc. bought a new stake in shares of  Abbott Laboratories during the fourth quarter valued at approximately $202,000.  Finally, Buffalo Business &amp; Estate Services Ltd. bought a new stake in shares of  Abbott Laboratories during the fourth quarter valued at approximately $280,000. 75.18% of the stock is currently owned by institutional investors. </p><h2>Analysts Set New Price Targets</h2><p>Several equities research analysts recently weighed in on ABT shares. Piper Sandler reduced their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an &#34;overweight&#34; rating for the company in a research report on Friday, January 23rd. Citigroup reduced their price objective on Abbott Laboratories from $140.00 to $136.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, March 11th. Royal Bank Of Canada reduced their price objective on Abbott Laboratories from $147.00 to $135.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, January 23rd. Weiss Ratings downgraded Abbott Laboratories from a &#34;buy (b-)&#34; rating to a &#34;hold (c+)&#34; rating in a report on Monday, January 26th. Finally, Oppenheimer reduced their price objective on Abbott Laboratories from $140.00 to $132.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned  a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $135.68.</p><ul><li>Is Abbott’s January Pullback a Good Time to Buy? </li></ul><p><b>Read Our Latest Analysis on ABT</b></p><h2>Abbott Laboratories Stock Performance</h2><p>Shares of ABT opened at $102.30 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a one year low of $100.88 and a one year high of $139.06. The firm has a market capitalization of $178.16 billion, a P/E ratio of 27.50, a PEG ratio of 1.64 and a beta of 0.79. The business has a fifty day moving average of $109.35 and a 200 day moving average of $120.71. </p><ul><li>2 Healthcare Names That Could Get a Big Boost From Earnings</li></ul><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analysts' expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business's revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS.  As a group, sell-side analysts anticipate that  Abbott Laboratories will post 5.14 EPS for the current year. </p><h2>Abbott Laboratories Announces Dividend</h2><p>The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 67.74%. </p><h2>Insiders Place Their Bets</h2><p>In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares of the company's stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP John A. Jr. Mccoy sold 585 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president directly owned 24,628 shares of the company's stock, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by company insiders. </p><h2>Abbott Laboratories Company Profile</h2> (Free Report)<p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.  </p><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Abbott Laboratories</li></ul><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2><p>Before you consider Abbott Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Portside Wealth Group LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 41.8% in Q4, selling 13,652 shares, leaving it with 19,016 shares valued at $2.38 million. Other institutional investors also adjusted their holdings. Analysts have lowered price targets for Abbott, with an average target of $135.68. Abbott's stock opened at $102.30, with a market cap of $178.16 billion. The company reported Q4 earnings of $1.50 per share, meeting expectations, and announced a quarterly dividend to be paid on May 15th.</p>

Market Beat

Abacus Global

iShares Global Healthcare

iShares US Medical Devices

SPDR S&P Health Equip

VG Health

Health Care Select Sector SPDR

iShares US Pharma

Abbott Laboratories

Portside Wealth Group LLC Sells 13,652 Shares of Abbott Laboratories $ABT